GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Price-to-Free-Cash-Flow

Tenax Therapeutics (Tenax Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 29, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-29), Tenax Therapeutics's share price is $3.67. Tenax Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.13. Hence, Tenax Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Tenax Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

TENX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.135
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Tenax Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-3.93. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-29.13.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 75.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 54.60% per year.

During the past 13 years, Tenax Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 75.10% per year. The lowest was -8.90% per year. And the median was 34.60% per year.


Tenax Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Tenax Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Price-to-Free-Cash-Flow Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tenax Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tenax Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Tenax Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's Price-to-Free-Cash-Flow falls into.



Tenax Therapeutics Price-to-Free-Cash-Flow Calculation

Tenax Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.67/-29.128
=N/A

Tenax Therapeutics's Share Price of today is $3.67.
Tenax Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Tenax Therapeutics  (NAS:TENX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Tenax Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus